• IL-1β is a member of the interleukin 1 family of cytokines. (wikipedia.org)
  • Examples of cytokines used to treat kidney cancer include interferon alfa and interleukin 2 ( IL-2, aldesleukin, or proleukin). (epnet.com)
  • Pathogenesis of dry skin in type 2 diabetes mellitus (T2DM) rises from the chronic hyperglycemia causing an increase in advanced glycation end-products (AGEs), proinflammatory cytokines, and oxidative stress. (hindawi.com)
  • iNOS is expressed in liver and inducible by a combination of lipopolysaccharide and certain cytokines. (thermofisher.com)
  • T helper (Th) 2 cells, which recruit and accumulate in the lungs and produce a range of different effector cytokines. (cdc.gov)
  • Previously, we have shown in a mouse model that exposure to hog dust extract (HDE) collected from a CAFO results in the activation of protein kinase C (PKC), elevated lavage fluid cytokines/chemokines including interleukin-6 (IL-6), and the development of significant lung pathology. (cdc.gov)
  • Unituxin is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. (nih.gov)
  • interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). (godandprostate.net)
  • Interleukin-1 beta (IL-1β) also known as leukocytic pyrogen, leukocytic endogenous mediator, mononuclear cell factor, lymphocyte activating factor and other names, is a cytokine protein that in humans is encoded by the IL1B gene. (wikipedia.org)
  • The induction of cyclooxygenase-2 (PTGS2/COX2) by this cytokine in the central nervous system (CNS) is found to contribute to inflammatory pain hypersensitivity. (wikipedia.org)
  • This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. (wikipedia.org)
  • Interleukin-23 ( IL-23 ) is a heterodimeric cytokine composed of an IL12B ( IL-12p40 ) subunit (that is shared with IL12 ) and the IL23A ( IL-23p19 ) subunit. (wikidoc.org)
  • The combination of LD IL-2/CTLA4-Ig significantly decreased the M1 phenotype and cytokine production and maintained Treg viability. (businesswire.com)
  • Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT), a trial of intermittent recombinant interleukin-2 (rIL-2) with cART vs. cART alone (control arm) in HIV-infected adults with CD4 counts =300cells/µL, offered the opportunity to explore associations between bacterial pneumonia and rIL-2, a cytokine that increases the risk of some bacterial infections. (figshare.com)
  • Currently, several monoclonal antibodies, such as dupilumab, mepolizumab and benralizumab, have been approved to target cytokine proteins like interleukin-4, interleukin-5 and interleukin-13, and these drugs are known to be effective in treating severe type 2 asthma. (nationaljewish.org)
  • Additionally, alcohol inhibits the lipopolysaccharide (LPS)-induced inflammatory cytokine, interleukin-6 (IL-6), via the p38 ERK1/2 MAPK pathway [ 9 ]. (cdc.gov)
  • In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. (ascopost.com)
  • In 185 patients with locally advanced stage III or stage IV melanoma, patients receiving gp100 plus interleukin-2 had higher response rates and progression-free survival (PFS) than did patients taking interleukin-2 alone. (hcplive.com)
  • A combination of BRAF inhibitor, dabrafenib, and MEK inhibitor, trametinib, has shown promise in patients with advanced melanoma, including fewer serious side effects than the current standard single-agent BRAF-targeted therapy, vemurafenib. (hcplive.com)
  • The phase III COMBI-d trial will evaluate the combination of the two investigational agents versus dabrafenib alone in stopping or slowing the progression of metastatic melanoma, with a primary endpoint of PFS. (hcplive.com)
  • gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (hcplive.com)
  • 1 , 2 ] Since the early 2000s, the incidence of melanoma in people younger than 50 years declined by about 1% per year in men and stabilized in women. (cancer.gov)
  • Interleukin-2 (IL-2) was the last drug approved to treat advanced melanoma, but 85% of patients derive no benefit from this drug. (centerwatch.com)
  • The consortium approach to research will address the growing recognition that melanoma patients will need combination therapies to meaningfully increase survival. (centerwatch.com)
  • Background: High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma. (umn.edu)
  • The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2. (umn.edu)
  • Patients and Methods: A retrospective analysis was performed on all adult patients with stage IV melanoma treated with HD IL-2 from January 2000 to October 2008 at the University of Minnesota. (umn.edu)
  • Results: Fifteen patients with metastatic melanoma had been treated with HD IL-2. (umn.edu)
  • Powell, S & Dudek, AZ 2009, ' Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases ', Anticancer Research , vol. 29, no. 10, pp. 4189-4193. (umn.edu)
  • Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA). (news-medical.net)
  • Evan J. Lipson, MD, of Johns Hopkins University, discusses primary phase III results from the RELATIVITY-047 study, which showed that relatlimab plus nivolumab as a fixed-dose combination may improve progression-free survival compared with nivolumab monotherapy in patients with advanced melanoma. (ascopost.com)
  • Angiosarcoma is rare, accounting for less than 2% of all soft-tissue sarcomas, and may vary from highly differentiated tumors to those with significant anaplasia, often making these tumors difficult to differentiate from melanoma or carcinoma. (medscape.com)
  • In protocol 2, 36 patients received ipilimumab with interleukin-2. (nih.gov)
  • The combination of ipilimumab and interleukin-2 seems to have an increased CR rate, but this needs to be tested in a randomized trial. (nih.gov)
  • Next, the effect of complete and incomplete signalling on B lymphocyte activation leading to cell cycle entry, IL-2 production, functional IL-2 receptor (IL-2R) expression, and DNA synthesis was examined. (tmc.edu)
  • Additional signals transduced by the interaction of autocrine IL-2 and functional IL-2 receptor on rabbit B cells were found to be necessary to drive these cells to S phase, after initial activation caused by simultaneous increase in (Ca$\sp2+\rbrack\sb{\rm i}$ and PKC activation had induced cell cycle entry, IL-2 production, and functional IL-2 receptor expression. (tmc.edu)
  • It was not until 1984 that interleukin 1 was discovered to consist of two distinct proteins, now called interleukin-1 alpha and interleukin-1 beta. (wikipedia.org)
  • PLX-R18 cells, derived from mesenchymal-like cells collected from donated placentas, are designed to release a combination of therapeutic proteins to jumpstart the regeneration of a poorly functioning hematopoietic system. (drugdiscoverynews.com)
  • In seven patients with metastasized RCC, who were treated with either interferon-alpha (IFN-α) monotherapy or a combination of IFN-α, interleukin-2 and 5-fluorouracil, FDG-PET was performed prior and after 5 and 9 weeks of treatment. (urotoday.com)
  • In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. (worldpharmanews.com)
  • COYA 301 is a proprietary investigational recombinant human low dose IL-2 biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a dual-mechanism investigational biologic combination comprised of proprietary low dose IL-2 and CTLA-4 Ig. (businesswire.com)
  • Subjects were divided into four groups that received either subcutaneous doses of itepekimab, dupilumab, a combination of both, or a placebo, every two weeks for 12 weeks. (nationaljewish.org)
  • Expanded access and an increased flow of information will allow researchers to systematically explore various combinations of therapeutic agents, from different pharma companies including those currently being tested in phase II and III clinical trials only as standalone therapies. (centerwatch.com)
  • The companies believe it has the potential to be a best-in-class IL-2 therapeutic for solid tumors. (biospace.com)
  • A novel immunotherapeutic combination-this one targeting the LAG-3 (lymphocyte-activation gene 3) and PD-1 immune checkpoints-delayed time to disease progression significantly more. (ascopost.com)
  • The elaboration of interleukin-8 (IL-8) and tumor growth factor alpha (TGFa) by normal human skin keratinocytes in- vitro following exposure to benzene and its metabolic products was assessed. (cdc.gov)
  • In contrast to the isolated eleutherosides B and eleutherosides E and the remixed eleutherosides B and E, the whole ethanolic fluid extract of Eleutherococcus senticosus was able to induce and enhance interleukin 1 and interleukin-6 but not interleukin-2 production in vitro. (thieme-connect.com)
  • Im Gegensatz zu den isolierten Eleutherosiden B und E, allein oder in Combination, war dergesamte alkoholische Flüssigextrakt von Eleutherococcus senticasus in der Lage, die In vitro Produktion von Interleukin 1 und Interleukin 6, aber nicht die von Interleukin-2 zu induzieren und zu verstärken. (thieme-connect.com)
  • AIM 1: Use of a recently introduced in vitro human B cell culture system to determine: (i) if IL-4+low-dose IL-2 is an effective strategy to restore B cell homeostasis, (ii) if IL-4 acts through pSTAT6 to induce CD25 to enable low-dose IL-2 to induce a regulatory signaling in suppressing pathogenic B-cell development in SLE. (lupusresearch.org)
  • Itepekimab is a novel monoclonal antibody designed to target interleukin-33. (nationaljewish.org)
  • Avoid combination because corticosteroids can potentially diminish the antineoplastic effects of aldesleukin. (medscape.com)
  • B) antimycobacterial drug combinations, antiretroviral therapy (ART), and trimethoprim/sulfamethoxazole prophylaxis. (cdc.gov)
  • Overall survival (OS) was significantly longer in the combination therapy group. (hcplive.com)
  • Two patients had complete resolution of brain lesions after HD IL-2 therapy. (umn.edu)
  • Twelve out of the 15 patients received 2 courses of therapy. (umn.edu)
  • Conclusion: We propose further evaluation of HD IL-2 in patients with brain metastases because this patient population is typically considered ineligible for HD IL-2 therapy. (umn.edu)
  • Nonspecific immunotherapies, such as interleukin-2 and interferons, are typically given in combination with other cancer treatments, such as chemotherapy or radiation therapy. (canceraustralia.gov.au)
  • Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), inter-feron-alfa (IFN) as single agents or in combina-tion, with or without chemotherapy. (thieme-connect.de)
  • 2) therapy of at least 10 patients with mRCC per year. (thieme-connect.de)
  • EpiCept subsequently agreed on the outline of a proposed Phase III combination therapy study with FDA, and this will be carried out under a Special Protocol Assessment. (genengnews.com)
  • Clearance on this basis means EpiCept is having to perform post-approval studies to further elucidate the clinical pharmacology of Ceplene by assessing certain biomarkers in AML patients in first remission and to assess the effect of combination therapy using Ceplene and IL-2 on the development of minimal residual disease in the same patient population. (genengnews.com)
  • The focus of this application is the development of a combination of interleukin-4 (IL-4) with low-dose IL-2 as a novel therapy for SLE. (lupusresearch.org)
  • The feasibility of the proposed therapy is supported by the clinical trials of IL-4 and low-dose IL-2 as monotherapies in SLE and other autoimmune diseases. (lupusresearch.org)
  • BACKGROUND AND OBJECTIVES Bacterial pneumonia still contributes to morbidity/mortality in HIV infection despite effective combination antiretroviral therapy (cART). (figshare.com)
  • Multimodal therapy involves using a combination of treatments, such as surgery, chemotherapy, and radiation therapy, to treat mesothelioma. (mediaindoensia.com)
  • Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. (rochester.edu)
  • Molecular diagnosis & therapy 2015 Apr 19 (2): 99-106. (cdc.gov)
  • Its lead product candidate is THOR-707, a form of interleukin-2 (IL-2) that is being developed in multiple solid tumors types as a monotherapy and in combination with checkpoint inhibitors. (biospace.com)
  • The hypothesis that IL-2, acts in late G$\sb1$ and is required for DNA synthesis in B cells was supported by comparing IL-2 production and DNA synthesis in peripheral blood cells and purified B cells, kinetic analysis of these events in B cells, effects of anti-IL-2 antibody and PKC inhibitors, and by the response of G$\sb1$ B cells. (tmc.edu)
  • The aim of this study was to systemically review the efficacy and safety of inhibitors of interleukin 6 (IL-6): clazakizumab, IL-12/23: ustekinumab, and IL-17A: secukinumab, brodalumab, and ixekizumab in psoriatic arthritis (PsA). (medscape.com)
  • Results of a phase I/II study exploring the combination of these two investigational targeted therapies were presented in a press briefing at the 2012 American Society of Clinical Oncology (ASCO) meeting. (hcplive.com)
  • Academic institutions often do not have the capacity to test investigative drugs without support from pharmaceutical companies, and pharmaceutical companies have not been able to test combination therapies of investigational drugs without support from research and academic institutions. (centerwatch.com)
  • In some cases, IL-2 results in shrinking the tumor. (epnet.com)
  • Secretion of interleukin-6, tumor necrosis factor alpha, and MCP-1 was not significantly affected by BQ, HQ, or BZT. (cdc.gov)
  • After tumor excision from the patient, tumor is digested into small fragments or a single cell suspension and then expanded in culture with IL-2. (biomedcentral.com)
  • Interleukin (IL)-9-producing subset called Th9 cell, Th22 cells which primarily secrete IL-22, IL-13 and tumor necrosis factor- and Th25 cells via producing IL-25 are believed to be important for initiating allergic reactions and developing airway inflammation. (cdc.gov)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • than were interleukin-2-treated patients (16% vs 6%, P =.03) Patients receiving the combination also had increased average survival (by 7 months) over the single agent-from 11.1 months to 17.8 months. (hcplive.com)
  • The highest PFS was achieved in 24 patients who received 150 mg of dabrafenib twice daily and 2 mg of trametinib once daily. (hcplive.com)
  • Patients in protocol 2 had a 17% complete response (CR) rate, compared with 7% in protocol 1 and 6% in protocol 3. (nih.gov)
  • Severe peripheral sensory neuropathy ranged from 2% to 9% in patients with neuroblastoma. (nih.gov)
  • In clinical studies of patients with high-risk neuroblastoma, Grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. (nih.gov)
  • There were 4 patients exhibiting some response, with 1 complete response (CR), 1 partial response (PR), 1 mixed response (MR) and 2 stable disease (SD). (umn.edu)
  • However, EpiCept says more detailed analysis of subgroup data suggests that patients with AML of monocyte origin achieve a statistically significant increase in overall survival when treated using Ceplene plus low-dose IL-2. (genengnews.com)
  • Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. (nwbio.com)
  • The experimental data generated in cell samples from ALS patients highlight the significant positive effect of LD IL-2/CTLA4-Ig and other Treg-enhancing therapies in reducing the inflammatory environment observed in ALS. (businesswire.com)
  • Combination of oral and topical Centella asiatica (CA) is expected to treat dry skin in T2DM patients more effectively through decreasing N(6)-carboxymethyl-lysine (CML) and interleukin-1 α (IL-1 α ) and increasing superoxide dismutase (SOD) activity. (hindawi.com)
  • CAo and CAt combination can be used to significantly improve dry skin condition through increasing SOD activity in T2DM patients with controlled blood glucose. (hindawi.com)
  • The first part of our study will test interleukin-4 and low doses of interleukin-2 on isolated cells from patients with lupus. (lupusresearch.org)
  • The next step, if results from those experiments are positive, could be clinical trials of interleukin-4 and low doses of interleukin-2 in patients with lupus. (lupusresearch.org)
  • The recommended starting dose of KINERET is 1-2 mg/kg daily for NOMID patients. (drugs.com)
  • By the end, an event indicating a loss of asthma control occurred in 22% of the patients in the itepekimab group versus 41% of those in the placebo group, 27% of those in the combination group, and 19% of those in the dupilumab group. (nationaljewish.org)
  • Results: Change of modified Preclinical Alzheimer's Cognitive Composite (mPACC) in cognitively unimpaired (CU) was best predicted by p-tau/Aβ42 alone (R 2 ≥ 0.31) or together with NfL (R 2 = 0.25), while p-tau/Aβ42 (R 2 ≥ 0.19) was sufficient to accurately predict change of the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) patients. (lu.se)
  • I stayed at MD Anderson for a week each time I had an infusion of biochemotherapy - a treatment combining cisplatin, vinblastine, interleukin-2, dacarbazine and interferon. (mdanderson.org)
  • Ideally a three-fold combination will be developed addressing inflammation as well as cartilage and bone repair. (nanowerk.com)
  • To achieve this researchers will use interleukin-10 for reduction of inflammation, BMP-2 (bone morphogenetic protein) for regeneration of bone and TGF-ß (transforming growth factor) for regeneration of cartilage. (nanowerk.com)
  • Increasing incidence of diabetes creates a growing healthcare financial burden in Indonesia as it is expected to cost 1.2 million US dollar by 2020 [ 1 , 2 ]. (hindawi.com)
  • Psoriatic arthritis (PsA) is an inflammatory arthritis with no gender preference and has an estimated incidence of 6 per 100,000 per year and a prevalence of 1 to 2 per 1000 in the general population. (medscape.com)
  • HA551 trade name] is indicated in combination with at least one other antiretroviral product for the treatment of HIV-1 infection in adults and adolescents over 10 years of age and weighing at least 30 kg. (who.int)
  • NLRP3 (contains three domain: pyrin domain, a nucleotide-binding domain and a leucine-rich repeat) type of inflammasome is activated by various stimuli and there are documented several diseases connected to NLRP3 activation like type 2 diabetes mellitus , Alzheimer's disease, obesity and atherosclerosis. (wikipedia.org)
  • A few of these inflammatory responses, such as inflammatory cell recruitment, can be modulated by alcohol exposure [ 1 , 2 , 3 , 4 ]. (cdc.gov)
  • This study evaluated the effects of Ceplene plus low-dose IL-2 in terms of leukemia-free survival time and was not powered to determine overall survival. (genengnews.com)
  • IL-23 was first described by Robert Kastelein and colleagues at the DNAX research institute using a combination of computational , biochemical and cellular immunology approaches. (wikidoc.org)
  • Immunology;153(2): 268-278, 2018 02. (bvsalud.org)
  • Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. (bvsalud.org)
  • T helper type 2 (Th2) cells , type 2 innate lymphoid cells (ILC2s) and eosinophil progenitors have previously been described to produce interleukin-5 ( IL-5 ) in the airways upon allergen provocation or by direct administration of IL-33 . (bvsalud.org)
  • Administer intravenous opioid prior to, during, and for 2 hours following completion of the Unituxin infusion. (nih.gov)
  • HD IL-2 was given intravenously every 8 hours at 600,000 IU/kg for a maximum of 14 doses per course. (umn.edu)
  • Researchers are exploring the use of combination therapies to reach these goals. (hcplive.com)
  • The 150 mg/2 mg dose will be evaluated further in a phase III clinical trial. (hcplive.com)
  • Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. (cdc.gov)
  • During the neutropenic phase (2-4 wk) the patient essentially has no effective immune system. (medscape.com)
  • Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors. (rochester.edu)
  • Introduction: Our objective was determining the optimal combinations of cerebrospinal fluid (CSF) biomarkers for predicting disease progression in Alzheimer's disease (AD) and other neurodegenerative diseases. (lu.se)
  • therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases ( 2 , 3 ). (cdc.gov)
  • Calcium ionophore, ionomycin, and phorbol myristate acetate (PMA) were used to activate rabbit peripheral blood B cells to study the role of increased intracellular calcium ion concentration ( (Ca$\sp2+\rbrack\sb{\rm i}$), protein kinase C (PKC) activation, and autocrine interleukin (IL-2) in inducing cell cycle entry and maintaining activation to DNA synthesis. (tmc.edu)
  • Specifically, the IL-4R signaling pathways upregulate CD25 on B cells, thereby promoting formation of the high affinity IL-2R complexes required for low-dose IL-2 signaling that induces a regulatory signal that restores B cells to the rNAV stage. (lupusresearch.org)
  • In this study production levels of interleukins (IL)-12 and IL-13 were measured by commercial ELISA in culture supernatants of mitogen-stimulated peripheral blood mononuclear cells from 30 non-splenectomized beta-thalassaemia cases with iron overload and 20 age- and sex-matched healthy individuals. (who.int)
  • Dans la présente étude, les taux de production des interleukines 12 et 13 (IL-12 et IL-13) ont été mesurés à l'aide de la méthode ELISA dans les surnageants de culture de cellules mononucléées de sang périphérique stimulées par des mitogènes chez 30 cas de bêta-thalassémie non splénectomisés présentant une surcharge martiale ainsi que chez 20 individus en bonne santé appariés pour l'âge et le sexe. (who.int)
  • In this manner e.g. magnetic nanoparticles warm up, when placed in a magnetic field, which in turn leads to activation of a heat shock (HSP70) gene switch that regulates production of BMP-2. (nanowerk.com)
  • The effective concentration of the whole ethanolic extract ranged from 1.0-0.1 mg/ml for the enhancement of interleukinla production and 1.0-0.03 mg/ml for the enhancement of interleukin-6 production. (thieme-connect.com)
  • It was observed that cell cycle entry could be induced by signals provided by each reagent alone, but IL-2 production, IL-2R expression, and progression to DNA synthesis required activation with both reagents. (tmc.edu)
  • Incomplete activation with ionomycin or PMA alone altered the responsiveness of B cells to further stimulation only in the case of ionomycin, and the unresponsiveness of these cells was apparently due to a lack of functional IL-2R expression on these cells, even though IL-2 production was maintained. (tmc.edu)
  • IL-33 -mediated eosinophil production was indeed dependent on IL-5 as both airway and bone marrow eosinophils decreased in mice treated with anti- IL-5 in combination with IL-33 . (bvsalud.org)
  • 1976. Combination of genetic factors and chronic exposure to benzene in the aetiology of leukaemia. (cdc.gov)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • Results of this study further support the potential of COYA 302 (LD IL-2 and CTLA4-Ig) to address the multiple pathways involved in the progression and severity of ALS. (businesswire.com)
  • The international research team investigated the efficacy of itepekimab on its own and in combination with dupilumab in a multicenter, randomized, double-blind, placebo-controlled trial at 70 sites. (nationaljewish.org)
  • IL-2 treatment is not appropriate for all people with metastatic kidney cancer because of the serious side effects. (epnet.com)
  • The nausea and neuropathy caused by that combination were sometimes hard to deal with, but the results of my treatment were extraordinary. (mdanderson.org)
  • ii) demonstrate that exposure of human B cells to IL-4 prior to treatment with low-dose IL-2 blocks the anti-Ig, IL-21, IFN-gamma, TLR7 and BAFF-stimulated development of T-bet+CD11c+IgD-CD27- double negative 2 (DN2) B cells and CD27+CD38+ plasmablasts (PBs) and preserves the B cells in the resting naïve (rNAV) state. (lupusresearch.org)
  • Then TIL is further expanded in a rapid expansion phase (REP) in response to stimulators, such as IL-2 and/or feeder cells. (biomedcentral.com)
  • Research led by Michael E. Wechsler, MD, MMSc , director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Medicine . (nationaljewish.org)
  • Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. (cdc.gov)